The Experts below are selected from a list of 16509 Experts worldwide ranked by ideXlab platform
Johan Lennartsson - One of the best experts on this subject based on the ideXlab platform.
-
dual specificity Phosphatase dusp 4 is induced by platelet derived growth factor bb in an erk1 2 stat3 and p53 dependent manner
Biochemical and Biophysical Research Communications, 2019Co-Authors: Glenda Eger, Niki Sarri, Charlotte Rorsman, Johan LennartssonAbstract:Abstract Dual specificity Phosphatase (DUSP) 4 has been described as a negative regulator of MAP kinase signaling, in particular for the ERK1/2 and JNK pathways. We found that DUSP4 expression was upregulated in response to prolonged platelet-derived growth factor (PDGF)-BB stimulation. The PDGF-BB-induced DUSP4 expression was dependent on ERK1/2, STAT3 and p53. We found that inhibition of ERK1/2 effectively reduced DUSP4 mRNA levels, whereas STAT3 was necessary for maintaining p53 expression. p53 has binding sites in the DUSP4 promoter and was found to promote DUSP4 expression.
-
dual specificity Phosphatase dusp 4 is induced by platelet derived growth factor bb in an erk1 2 stat3 and p53 dependent manner
Biochemical and Biophysical Research Communications, 2019Co-Authors: Glenda Eger, Niki Sarri, Charlotte Rorsman, Johan Lennartsson, Carlhenrik HeldinAbstract:Abstract Dual specificity Phosphatase (DUSP) 4 has been described as a negative regulator of MAP kinase signaling, in particular for the ERK1/2 and JNK pathways. We found that DUSP4 expression was upregulated in response to prolonged platelet-derived growth factor (PDGF)-BB stimulation. The PDGF-BB-induced DUSP4 expression was dependent on ERK1/2, STAT3 and p53. We found that inhibition of ERK1/2 effectively reduced DUSP4 mRNA levels, whereas STAT3 was necessary for maintaining p53 expression. p53 has binding sites in the DUSP4 promoter and was found to promote DUSP4 expression.
Wei Lu - One of the best experts on this subject based on the ideXlab platform.
-
dual specificity Phosphatase 4 gene expression in association with triple negative breast cancer outcome
Breast Cancer Research and Treatment, 2014Co-Authors: Michelle L Baglia, Justin M Balko, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Triple-negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. Dual specificity Phosphatase 4 (DUSP4) has recently been suggested as a potential marker of chemotherapy resistance for TNBC. DUSP4 gene expression levels were measured in breast cancer tissue from 469 TNBC patients aged 20–75 years who participated in the Shanghai Breast Cancer Survival Study, and their association with recurrence/breast cancer mortality and total mortality was evaluated. Information on breast cancer diagnosis, treatment, and disease progression was collected via medical chart review and multiple in-person follow-up surveys. A Cox regression model was applied in the data analyses. Over a median follow-up of 5.3 years (range: 0.7–8.9 years), 100 deaths and 92 recurrences/breast cancer deaths were documented. Expression levels of transcript variant 1 (NM_001394) and transcript variant 2 (NM_057158) of the DUSP4 gene were studied and were highly correlated (r = 0.76). Low DUSP4 expression levels, particularly of variant 1, were associated with both increased recurrence/breast cancer mortality and increased overall mortality. Hazard ratios with adjustment for age at diagnosis and TNM stage associated with below versus above the median expression level were 1.97 (95 % confidence interval (CI): 1.27–3.05) for recurrence/breast cancer mortality and 2.09 (95 % CI: 1.38–3.17) for overall mortality. Additional adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, and grade did not materially alter the observed associations. Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors.
-
dual specificity Phosphatase 4 gene expression in association with triple negative breast cancer outcome
Breast Cancer Research and Treatment, 2014Co-Authors: Michelle L Baglia, Justin M Balko, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Triple-negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. Dual specificity Phosphatase 4 (DUSP4) has recently been suggested as a potential marker of chemotherapy resistance for TNBC. DUSP4 gene expression levels were measured in breast cancer tissue from 469 TNBC patients aged 20–75 years who participated in the Shanghai Breast Cancer Survival Study, and their association with recurrence/breast cancer mortality and total mortality was evaluated. Information on breast cancer diagnosis, treatment, and disease progression was collected via medical chart review and multiple in-person follow-up surveys. A Cox regression model was applied in the data analyses. Over a median follow-up of 5.3 years (range: 0.7–8.9 years), 100 deaths and 92 recurrences/breast cancer deaths were documented. Expression levels of transcript variant 1 (NM_001394) and transcript variant 2 (NM_057158) of the DUSP4 gene were studied and were highly correlated (r = 0.76). Low DUSP4 expression levels, particularly of variant 1, were associated with both increased recurrence/breast cancer mortality and increased overall mortality. Hazard ratios with adjustment for age at diagnosis and TNM stage associated with below versus above the median expression level were 1.97 (95 % confidence interval (CI): 1.27–3.05) for recurrence/breast cancer mortality and 2.09 (95 % CI: 1.38–3.17) for overall mortality. Additional adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, and grade did not materially alter the observed associations. Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors.
-
abstract 3265 dual specificity Phosphatase 4 gene expression in triple negative breast cancer
Cancer Research, 2014Co-Authors: Michelle L Baglia, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background Triple negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. A recent report suggested that dual specificity Phosphatase 4 (DUSP4) may be a potential marker of chemotherapy resistance for TNBC. Methods We measured the DUSP4 gene expression levels in breast cancer tissue from 469 TNBC patients who participated in the Shanghai Breast Cancer Survival Study and evaluated their association with breast cancer recurrence/breast cancer mortality and total mortality. Study participants were diagnosed with incident breast cancer between March 2002 and April 2006 and aged between 20 and 75 years. Information on breast cancer diagnosis and treatment, as well as demographic, lifestyle, and disease progression information, were collected approximately 6 months after cancer diagnosis and reassessed at 18, 36, and 60 months after diagnosis in follow-up interviews. Expression levels of transcript variant 1 (NM\_001394) and transcript variant 2 (NM\_057158) of DUSP4 gene were measured by the NanoString nCounter assay using RNA obtained from formalin-fixed, paraffin-embedded tissue sections. Cox regression analysis was applied in the data analyses with adjustment for clinical and demographic factors. Results Of the 469 TNBC participants in this study, 100 deaths and 92 recurrences/breast cancer deaths were documented over a median follow-up of 5.3 years (range, 0.7-8.9 years). The expression of the two DUSP4 isoforms were highly correlated (r=0.76). Low DUSP4, particularly variant 1 (NM_001394), expression levels were associated with increased recurrence/breast cancer mortality and overall mortality. After adjustment for age at diagnosis and TNM stage, the hazard ratios comparing those with DUSP4 (variant 1) expression levels below the median to those above the median were 1.97 (95% confidence interval (CI): 1.27, 3.05) for recurrence/breast cancer mortality and 2.09 (95% CI: 1.38, 3.17) for overall mortality. Adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, or grade did not materially alter the observed association. Conclusion Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors. Citation Format: Michelle L. Baglia, Qiuyin Cai, Ying Zheng, Jie Wu, Yinghao Su, Fei Ye, Ping-Ping Bao, Hui Cai, Zhiguo Zhao, Wei Zheng, Wei Lu, Xiao-Ou Shu. Dual specificity Phosphatase 4 gene expression in triple negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3265. doi:10.1158/1538-7445.AM2014-3265
Michelle L Baglia - One of the best experts on this subject based on the ideXlab platform.
-
dual specificity Phosphatase 4 gene expression in association with triple negative breast cancer outcome
Breast Cancer Research and Treatment, 2014Co-Authors: Michelle L Baglia, Justin M Balko, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Triple-negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. Dual specificity Phosphatase 4 (DUSP4) has recently been suggested as a potential marker of chemotherapy resistance for TNBC. DUSP4 gene expression levels were measured in breast cancer tissue from 469 TNBC patients aged 20–75 years who participated in the Shanghai Breast Cancer Survival Study, and their association with recurrence/breast cancer mortality and total mortality was evaluated. Information on breast cancer diagnosis, treatment, and disease progression was collected via medical chart review and multiple in-person follow-up surveys. A Cox regression model was applied in the data analyses. Over a median follow-up of 5.3 years (range: 0.7–8.9 years), 100 deaths and 92 recurrences/breast cancer deaths were documented. Expression levels of transcript variant 1 (NM_001394) and transcript variant 2 (NM_057158) of the DUSP4 gene were studied and were highly correlated (r = 0.76). Low DUSP4 expression levels, particularly of variant 1, were associated with both increased recurrence/breast cancer mortality and increased overall mortality. Hazard ratios with adjustment for age at diagnosis and TNM stage associated with below versus above the median expression level were 1.97 (95 % confidence interval (CI): 1.27–3.05) for recurrence/breast cancer mortality and 2.09 (95 % CI: 1.38–3.17) for overall mortality. Additional adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, and grade did not materially alter the observed associations. Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors.
-
dual specificity Phosphatase 4 gene expression in association with triple negative breast cancer outcome
Breast Cancer Research and Treatment, 2014Co-Authors: Michelle L Baglia, Justin M Balko, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Triple-negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. Dual specificity Phosphatase 4 (DUSP4) has recently been suggested as a potential marker of chemotherapy resistance for TNBC. DUSP4 gene expression levels were measured in breast cancer tissue from 469 TNBC patients aged 20–75 years who participated in the Shanghai Breast Cancer Survival Study, and their association with recurrence/breast cancer mortality and total mortality was evaluated. Information on breast cancer diagnosis, treatment, and disease progression was collected via medical chart review and multiple in-person follow-up surveys. A Cox regression model was applied in the data analyses. Over a median follow-up of 5.3 years (range: 0.7–8.9 years), 100 deaths and 92 recurrences/breast cancer deaths were documented. Expression levels of transcript variant 1 (NM_001394) and transcript variant 2 (NM_057158) of the DUSP4 gene were studied and were highly correlated (r = 0.76). Low DUSP4 expression levels, particularly of variant 1, were associated with both increased recurrence/breast cancer mortality and increased overall mortality. Hazard ratios with adjustment for age at diagnosis and TNM stage associated with below versus above the median expression level were 1.97 (95 % confidence interval (CI): 1.27–3.05) for recurrence/breast cancer mortality and 2.09 (95 % CI: 1.38–3.17) for overall mortality. Additional adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, and grade did not materially alter the observed associations. Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors.
-
abstract 3265 dual specificity Phosphatase 4 gene expression in triple negative breast cancer
Cancer Research, 2014Co-Authors: Michelle L Baglia, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background Triple negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. A recent report suggested that dual specificity Phosphatase 4 (DUSP4) may be a potential marker of chemotherapy resistance for TNBC. Methods We measured the DUSP4 gene expression levels in breast cancer tissue from 469 TNBC patients who participated in the Shanghai Breast Cancer Survival Study and evaluated their association with breast cancer recurrence/breast cancer mortality and total mortality. Study participants were diagnosed with incident breast cancer between March 2002 and April 2006 and aged between 20 and 75 years. Information on breast cancer diagnosis and treatment, as well as demographic, lifestyle, and disease progression information, were collected approximately 6 months after cancer diagnosis and reassessed at 18, 36, and 60 months after diagnosis in follow-up interviews. Expression levels of transcript variant 1 (NM\_001394) and transcript variant 2 (NM\_057158) of DUSP4 gene were measured by the NanoString nCounter assay using RNA obtained from formalin-fixed, paraffin-embedded tissue sections. Cox regression analysis was applied in the data analyses with adjustment for clinical and demographic factors. Results Of the 469 TNBC participants in this study, 100 deaths and 92 recurrences/breast cancer deaths were documented over a median follow-up of 5.3 years (range, 0.7-8.9 years). The expression of the two DUSP4 isoforms were highly correlated (r=0.76). Low DUSP4, particularly variant 1 (NM_001394), expression levels were associated with increased recurrence/breast cancer mortality and overall mortality. After adjustment for age at diagnosis and TNM stage, the hazard ratios comparing those with DUSP4 (variant 1) expression levels below the median to those above the median were 1.97 (95% confidence interval (CI): 1.27, 3.05) for recurrence/breast cancer mortality and 2.09 (95% CI: 1.38, 3.17) for overall mortality. Adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, or grade did not materially alter the observed association. Conclusion Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors. Citation Format: Michelle L. Baglia, Qiuyin Cai, Ying Zheng, Jie Wu, Yinghao Su, Fei Ye, Ping-Ping Bao, Hui Cai, Zhiguo Zhao, Wei Zheng, Wei Lu, Xiao-Ou Shu. Dual specificity Phosphatase 4 gene expression in triple negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3265. doi:10.1158/1538-7445.AM2014-3265
Manhua Chen - One of the best experts on this subject based on the ideXlab platform.
-
dual specificity Phosphatase 26 protects against nonalcoholic fatty liver disease in mice through transforming growth factor beta activated kinase 1 suppression
Hepatology, 2019Co-Authors: Ping Ye, Wuping Xu, Xiangchao Ding, Sheng Le, Shanshan Chen, Manhua ChenAbstract:: Nonalcoholic fatty liver disease (NAFLD), which has a wide global distribution, includes different stages ranging from simple steatosis to nonalcoholic steatohepatitis, advanced fibrosis, and liver cirrhosis according to the degree of severity. Chronic low-grade inflammation, insulin resistance, and lipid accumulation are the leading causes of NAFLD. To date, no effective medicine for NAFLD has been approved by governmental agencies. Our study demonstrated that the expression of Dual-Specificity Phosphatase 26 (Dusp26), a member of the Dusp protein family, was decreased in the liver tissue of mice with hepatic steatosis and genetically obese (ob/ob) mice. In our study, hepatic steatosis, inflammatory responses, and insulin resistance were exacerbated in liver-specific Dusp26-knockout (KO) mice but ameliorated in liver-specific Dusp26-transgenic mice induced by a high-fat diet. In addition, the degree of liver fibrosis was aggravated in high-fat high-cholesterol diet-induced Dusp26-KO mice. We further found that the binding of Dusp26 to transforming growth factor beta-activated kinase 1 (TAK1) to block the phosphorylation of TAK1 regulated the TAK1-p38/c-Jun NH2-terminal kinase signaling axis to alleviate hepatic steatosis and metabolic disturbance. Conclusion: These findings suggest that Dusp26 is a good TAK1-dependent therapeutic target for NAFLD.
-
dual specificity Phosphatase 9 protects against nonalcoholic fatty liver disease in mice through ask1 suppression
Hepatology, 2019Co-Authors: Ping Ye, Mei Xiang, Yayun Wang, Hua Liao, Ling Huang, Manhua ChenAbstract:: Nonalcoholic fatty liver disease (NAFLD), ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis (NASH), is the leading cause of chronic liver diseases. Until now, no medications for NAFLD have been approved by relevant governmental agencies. Dual-Specificity Phosphatase 9 (Dusp9) is a member of the DUSP protein family. Dusp9 is expressed in insulin-sensitive tissues, and its expression may be modified with the development of insulin resistance (IR). However, the molecular targets and mechanisms of Dusp9 action on NAFLD and NASH remain poorly understood. In this study, using conditional liver-specific Dusp9-knockout (Dusp9-CKO) mice and Dusp9-transgenic mice, we showed that Dusp9 was a key suppressor of high-fat diet-induced hepatic steatosis and inflammatory responses and that Dusp9 deficiency aggravated high-fat high-cholesterol diet-induced liver fibrosis. Dusp9 was shown to exert its effects by blocking apoptosis signal-regulating kinase 1 (ASK1) phosphorylation and the subsequent activation of p38 and c-Jun NH2-terminal kinase signaling. Conclusion: Hepatocyte Dusp9 prevents NAFLD and NASH progression in mice, including lipid accumulation, glucose metabolism disorders, and enhanced inflammation and liver fibrosis, in an ASK1-dependent manner; these findings suggest that Dusp9 may be a promising therapeutic target for the treatment of NAFLD and NASH.
Jie Wu - One of the best experts on this subject based on the ideXlab platform.
-
dual specificity Phosphatase 4 gene expression in association with triple negative breast cancer outcome
Breast Cancer Research and Treatment, 2014Co-Authors: Michelle L Baglia, Justin M Balko, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Triple-negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. Dual specificity Phosphatase 4 (DUSP4) has recently been suggested as a potential marker of chemotherapy resistance for TNBC. DUSP4 gene expression levels were measured in breast cancer tissue from 469 TNBC patients aged 20–75 years who participated in the Shanghai Breast Cancer Survival Study, and their association with recurrence/breast cancer mortality and total mortality was evaluated. Information on breast cancer diagnosis, treatment, and disease progression was collected via medical chart review and multiple in-person follow-up surveys. A Cox regression model was applied in the data analyses. Over a median follow-up of 5.3 years (range: 0.7–8.9 years), 100 deaths and 92 recurrences/breast cancer deaths were documented. Expression levels of transcript variant 1 (NM_001394) and transcript variant 2 (NM_057158) of the DUSP4 gene were studied and were highly correlated (r = 0.76). Low DUSP4 expression levels, particularly of variant 1, were associated with both increased recurrence/breast cancer mortality and increased overall mortality. Hazard ratios with adjustment for age at diagnosis and TNM stage associated with below versus above the median expression level were 1.97 (95 % confidence interval (CI): 1.27–3.05) for recurrence/breast cancer mortality and 2.09 (95 % CI: 1.38–3.17) for overall mortality. Additional adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, and grade did not materially alter the observed associations. Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors.
-
dual specificity Phosphatase 4 gene expression in association with triple negative breast cancer outcome
Breast Cancer Research and Treatment, 2014Co-Authors: Michelle L Baglia, Justin M Balko, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Triple-negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. Dual specificity Phosphatase 4 (DUSP4) has recently been suggested as a potential marker of chemotherapy resistance for TNBC. DUSP4 gene expression levels were measured in breast cancer tissue from 469 TNBC patients aged 20–75 years who participated in the Shanghai Breast Cancer Survival Study, and their association with recurrence/breast cancer mortality and total mortality was evaluated. Information on breast cancer diagnosis, treatment, and disease progression was collected via medical chart review and multiple in-person follow-up surveys. A Cox regression model was applied in the data analyses. Over a median follow-up of 5.3 years (range: 0.7–8.9 years), 100 deaths and 92 recurrences/breast cancer deaths were documented. Expression levels of transcript variant 1 (NM_001394) and transcript variant 2 (NM_057158) of the DUSP4 gene were studied and were highly correlated (r = 0.76). Low DUSP4 expression levels, particularly of variant 1, were associated with both increased recurrence/breast cancer mortality and increased overall mortality. Hazard ratios with adjustment for age at diagnosis and TNM stage associated with below versus above the median expression level were 1.97 (95 % confidence interval (CI): 1.27–3.05) for recurrence/breast cancer mortality and 2.09 (95 % CI: 1.38–3.17) for overall mortality. Additional adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, and grade did not materially alter the observed associations. Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors.
-
abstract 3265 dual specificity Phosphatase 4 gene expression in triple negative breast cancer
Cancer Research, 2014Co-Authors: Michelle L Baglia, Yinghao Su, Jie Wu, Ying Zheng, Wei Zheng, Zhiguo Zhao, Fei Ye, Wei LuAbstract:Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background Triple negative breast cancer (TNBC) is an aggressive cancer with limited treatment options. A recent report suggested that dual specificity Phosphatase 4 (DUSP4) may be a potential marker of chemotherapy resistance for TNBC. Methods We measured the DUSP4 gene expression levels in breast cancer tissue from 469 TNBC patients who participated in the Shanghai Breast Cancer Survival Study and evaluated their association with breast cancer recurrence/breast cancer mortality and total mortality. Study participants were diagnosed with incident breast cancer between March 2002 and April 2006 and aged between 20 and 75 years. Information on breast cancer diagnosis and treatment, as well as demographic, lifestyle, and disease progression information, were collected approximately 6 months after cancer diagnosis and reassessed at 18, 36, and 60 months after diagnosis in follow-up interviews. Expression levels of transcript variant 1 (NM\_001394) and transcript variant 2 (NM\_057158) of DUSP4 gene were measured by the NanoString nCounter assay using RNA obtained from formalin-fixed, paraffin-embedded tissue sections. Cox regression analysis was applied in the data analyses with adjustment for clinical and demographic factors. Results Of the 469 TNBC participants in this study, 100 deaths and 92 recurrences/breast cancer deaths were documented over a median follow-up of 5.3 years (range, 0.7-8.9 years). The expression of the two DUSP4 isoforms were highly correlated (r=0.76). Low DUSP4, particularly variant 1 (NM_001394), expression levels were associated with increased recurrence/breast cancer mortality and overall mortality. After adjustment for age at diagnosis and TNM stage, the hazard ratios comparing those with DUSP4 (variant 1) expression levels below the median to those above the median were 1.97 (95% confidence interval (CI): 1.27, 3.05) for recurrence/breast cancer mortality and 2.09 (95% CI: 1.38, 3.17) for overall mortality. Adjustment for expression levels of MKI67 and TP53, common treatment types, breast cancer subtype, or grade did not materially alter the observed association. Conclusion Low DUSP4 expression levels predict recurrence and mortality in TNBC patients independently from known clinical and molecular predictors. Citation Format: Michelle L. Baglia, Qiuyin Cai, Ying Zheng, Jie Wu, Yinghao Su, Fei Ye, Ping-Ping Bao, Hui Cai, Zhiguo Zhao, Wei Zheng, Wei Lu, Xiao-Ou Shu. Dual specificity Phosphatase 4 gene expression in triple negative breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3265. doi:10.1158/1538-7445.AM2014-3265
